206 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author고성호-
dc.date.accessioned2019-12-04T04:48:21Z-
dc.date.available2019-12-04T04:48:21Z-
dc.date.issued2018-01-
dc.identifier.citationEXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, v. 14, no. 1, page. 83-90en_US
dc.identifier.issn1742-5255-
dc.identifier.issn1744-7607-
dc.identifier.urihttps://www.tandfonline.com/doi/full/10.1080/17425255.2018.1417387-
dc.identifier.urihttps://repository.hanyang.ac.kr/handle/20.500.11754/117156-
dc.description.abstractIntroduction: Levodopa (L-DOPA) is the most commonly used drug for Parkinson's disease (PD), but its long-term use is associated with various complications, including L-DOPA-induced dyskinesia (LID). Many studies have suggested that L-DOPA neurotoxicity and LID are associated with glycogen synthase kinase-3 (GSK-3) activation.Areas covered: LID is caused by striatal dopamine (DA) denervation in PD and pulsatile L-DOPA treatment. These factors lead to dysregulated DA transmission, abnormal intracellular signaling and transcription factors in striatal neurons, and altered gene expression and plasticity at corticostriatal synapses. The mechanisms of L-DOPA toxicity involve oxidative stress, L-DOPA oxidation to quinone, mitochondrial dysfunction, and a-synuclein. GSK-3 has been suggested to play key roles in all the mechanisms associated of L-DOPA toxicity and LID in PD.Expert opinion: GSK-3 plays critical roles in L-DOPA-induced neurotoxicity, and the development of specific methods to inhibit GSK-3 function may help prevent L-DOPA neurotoxicity and LID in PD. However, balanced GSK-3 inhibition and less beta-catenin degradation is essential for preventing LID, because too much GSK-3 inhibition increases beta-catenin levels, which is related to cancers.en_US
dc.description.sponsorshipThis work was supported by the Basic Science Research Program of the National Research Foundation of Korea funded by the Ministry of Science, ICT and Future Planning (2015R1A2A2A04004865), by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI17C2160), by the Korea Drug Development Fund (KDDF) funded by the Ministry of Science and ICT, Ministry of Trade, Industry & Energy, and Ministry of Health & Welfare (KDDF-201609-02, Republic of Korea), and by and the Medical Research Center (2017R1A5A2015395). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.en_US
dc.language.isoen_USen_US
dc.publisherTAYLOR & FRANCIS LTDen_US
dc.subjectParkinson's diseaseen_US
dc.subjectglycogen synthase kinase-3 (GSK-3)en_US
dc.subjectl-3en_US
dc.subject4-dihydroxyphenylalanine (L-DOPA)en_US
dc.subjectneurotoxicityen_US
dc.titleUnderstanding the role of glycogen synthase kinase-3 in L-DOPA-induced dyskinesia in Parkinson's diseaseen_US
dc.typeArticleen_US
dc.relation.no1-
dc.relation.volume14-
dc.identifier.doi10.1080/17425255.2018.1417387-
dc.relation.page83-90-
dc.relation.journalEXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY-
dc.contributor.googleauthorChoi, Hojin-
dc.contributor.googleauthorKoh, Seong-Ho-
dc.relation.code2018006102-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
dc.identifier.pidksh213-
Appears in Collections:
COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE